The underlying principle of the surgical treatment of non-small-cell lung c
ancer (NSCLC) is complete removal of the local/regional disease within the
thorax. Pulmonary resection should be as conservative as possible without c
ompromising the adequacy of tumor removal. A multitude of factors influence
the incidence and severity of complications following pulmonary resection
including the pre-operative physical and psychological status of the patien
t, the pathologic process requiring resection, the physiologic impact of th
e procedure, and the addition of pre-operative or postoperative adjuvant th
erapy. The insidious onset of interstitial changes on chest X-ray (CXR) 1 t
o 2 days after pulmonary resection forewarns of respiratory distress; howev
er, the pathophysiology of adult respiratory distress syndrome (ARDS) with
progression to respiratory failure requiring mechanical ventilation and adv
anced critical care often unfolds. Management of patients with severe respi
ratory failure remains primarily supportive. "Good critical care" is the ma
instay of therapy: this includes gentle mechanical ventilation to avoid ven
tilator-induced barotrauma and over-extension of remaining functional alveo
li, diuresis, infection identification and management, and nutritional supp
ort. New therapeutic strategies that may impact on outcomes in the adult po
pulation include pressure-limited ventilation (permissive hypercapnia), inv
erse ratio ventilation, high-frequency jet ventilation, high-frequency osci
llatory ventilation, intratracheal pulmonary ventilation, and prone positio
n ventilation. In addition, alternative therapies such as partial liquid ve
ntilation, inhaled nitric oxide, and extracorporeal techniques including ex
tracorporeal membrane oxygenation (ECMO), extracorporeal carbon dioxide rem
oval (ECCO2R), intravascular oxygenation (IVOX), and arteriovenous carbon d
ioxide removal (AVCO(2)R), provide additional modalities. A component of so
me or all of these strategies is finding a role in clinical practice. (C) 2
000 Wiley-Liss, Inc.